Innoviva (NASDAQ: INVA) is one of 104 publicly-traded companies in the “Pharmaceuticals” industry, but how does it compare to its competitors? We will compare Innoviva to similar companies based on the strength of its analyst recommendations, valuation, profitability, earnings, institutional ownership, risk and dividends.
This table compares Innoviva and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Innoviva has a beta of 2.51, meaning that its share price is 151% more volatile than the S&P 500. Comparatively, Innoviva’s competitors have a beta of 38.64, meaning that their average share price is 3,764% more volatile than the S&P 500.
Insider & Institutional Ownership
72.1% of Innoviva shares are held by institutional investors. Comparatively, 44.2% of shares of all “Pharmaceuticals” companies are held by institutional investors. 1.6% of Innoviva shares are held by insiders. Comparatively, 11.3% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Earnings and Valuation
This table compares Innoviva and its competitors gross revenue, earnings per share and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|Innoviva||$133.57 million||$59.53 million||15.24|
|Innoviva Competitors||$8.17 billion||$1.09 billion||123.24|
Innoviva’s competitors have higher revenue and earnings than Innoviva. Innoviva is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
This is a summary of recent recommendations for Innoviva and its competitors, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Innoviva currently has a consensus price target of $13.00, indicating a potential downside of 1.96%. As a group, “Pharmaceuticals” companies have a potential upside of 22.91%. Given Innoviva’s competitors stronger consensus rating and higher possible upside, analysts clearly believe Innoviva has less favorable growth aspects than its competitors.
Innoviva competitors beat Innoviva on 9 of the 13 factors compared.
Innoviva Company Profile
Innoviva, Inc., formerly Theravance, Inc., is engaged in the development, commercialization and financial management of bio-pharmaceuticals. It focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate (FF)/vilanterol (VI)) and ANORO ELLIPTA (umeclidinium bromide/vilanterol (UMEC/VI)). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement and the Strategic Alliance Agreement with GSK, the Company is eligible to receive the annual royalties from GSK on sales of RELVAR/BREO ELLIPTA. For other products combined with a LABA from the LABA collaboration, such as ANORO ELLIPTA, royalties are upward tiering and range from 6.5% to 10%. RELVAR/BREO is a once-a-day combination inhaled respiratory medicine consisting of a LABA (VI) and an inhaled corticosteroid (ICS), FF. ANORO ELLIPTA a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA.
What are top analysts saying about Innoviva Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Innoviva Inc. and related companies.